Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel) in Chemotherapy-naive Castration-Resistant Prostate Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 02 Sep 2014
At a glance
- Drugs Temsirolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2013 Planned end date changed from 1 Jun 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.